EYEGLASSES MAKE A FASHION STATEMENT

According to the Vision Council of America, approximately 75 percent of adults wear some sort of vision correction. People wear eyeglasses for different reasons. Some people are nearsighted and cannot see objects far away, while other people are farsighted and cannot see objects close by. Eyeglasses offer corrective vision for people who have difficulty seeing.

….FULL ARTICLE

LOCAL SPOTLIGHT - KENTUCKY HEALTH SOLUTIONS

It is that most wonderful time of the year—no, we are not talking about Christmas. It’s Medicare’s Annual Enrollment Season. Yes, it’s the time of the year when we stress and spend hours on the phone or online shopping for health coverage. The pain of having to shop health coverage, spend hours on the phone or online with one company vs another for our health insurance can be a daunting task. It does not matter if you are on Medicare or looking for your personal insurance, this can be one of the most….

….FULL ARTICLE

DO YOU HAVE 20/20 VISION

When you consider what defines healthy eyes, among the criteria is good vision. The American Optometric Association says the term 20/20 vision is used to express normal visual acuity (the clarity or sharpness of vision) measured at a distance of 20 feet. If you have 20/20 vision, you can see clearly at 20 feet what should normally be seen at that distance. Visual acuity is usually measured with a Snellen chart. It’s likely everyone has seen the Snellen chart – usually starting with a huge “E,” .....

….FULL ARTICLE

Use the buttons below to scroll through more great articles on health and wellness issues

MORE ARTICLES

Be Sociable, Share!

Share on Facebook Share on Twitter Share on Delicious Share on Digg Share on Google Bookmarks Share on LinkedIn Share on LiveJournal Share on Newsvine Share on Reddit Share on Stumble Upon Share on Tumblr

MORE FEATURE ARTICLES

CONTACT INFORMATION

© Health & Wellness Magazine - All rights reserved | Designed and Maintained by PurplePatch Innovations

MORE FROM ROCKPOINT PUBLISHING

HEALTH & WELLNESS MAGAZINE

HOME | FEATURE ARTICLES | COLUMNS | DIGITAL ISSUES | CALENDAR | DIRECTORY | ABOUT | CONTACT

subscribe to Health & Wellness


The results of two new randomized and controlled mental health research studies demonstrated that just one dose of psilocybin produces significant long-term improvements in patients with anxiety and depression. These findings, recently published in The Journal of Psychopharmacology, are potentially beneficial for individuals who are troubled by anxiety and depression.


Psilocybin is a hallucinogenic substance obtained from certain types of mushrooms indigenous to tropical and subtropical regions of South America, Mexico and the United States. Fifty-one adults participated in the double-blind crossover study at Johns Hopkins University. New York University was the second site. Stephen Ross, M.D., principal investigator of the NYU study and director of substance abuse services in the Department of Psychiatry at Langone Medical Center, said all patients received targeted counseling plus a 0.3 mg/kg dose of psilocybin at one of two treatment sessions. A vitamin placebo at the other session realized 80 percent of the subjects experienced a significant reduction in anxiety and depressive symptoms after six months. Furthermore, 80 percent of the subjects realized clinically significant decreases in symptomology six months after their final treatment session, suggesting there may be longer term benefits with less need for medication.


Further research with larger samples needs to be conducted,

INNOVATIVE RESEARCH FINDINGS SUGGEST NEW DIRECTION IN MENTAL HEALTH CARE

but it is clear these initial findings raise the issue that psilocybin holds true potential for treating anxiety and depression in patients with this diagnosis. These results represent a dramatic step forward in the mental health profession’s efforts to help some of the most seriously affected patients needing a more effective protocol of care and treatment for anxiety and depression.


Sources and Resources:


•  Hallucinogenic drug psilocybin eases existential anxiety in people with life threatening cancer. Baltimore, MD: Johns Hopkins University School of Medicine; December 1, 2016.

•  Single dose of hallucinogenic drug psilocybin relieves anxiety and depression in patients with advanced cancer. New York, NY: New York University Langone Medical Center; December 1, 2016.

DR. THOMAS W. MILLER, PH.D, ABPP

Thomas W. Miller, Ph.D., ABPP, is a professor emeritus and senior research scientist, Center for Health, Intervention and Prevention, University of Connecticut; retired service chief from the VA Medical Center; and tenured professor in the Department of Psychiatry, College of Medicine, University of Kentucky.

more articles by Dr thomas w. miller